|
The tumor immune microenvironment differs between metastatic castrate resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC). |
|
|
|
Research Funding - Genentech |
Travel, Accommodations, Expenses - Genentech |
|
|
Honoraria - Amgen; Astellas Pharma; Janssen-Cilag; Sanofi; Tolmar |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Janssen-Cilag; MSD Oncology; Sanofi; Tolmar |
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme; Merck Sharp & Dohme; Pfizer (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma |
|
|
Honoraria - Amgen; Merck; MSD Oncology; Roche; SERVIER; Sirtex Medical |
Research Funding - Amgen (Inst); Merck Serono (Inst); Roche (Inst); Ventana Medical Systems (Inst) |
Travel, Accommodations, Expenses - Servier |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck |
Consulting or Advisory Role - Amgen |
Speakers' Bureau - Bristol-Myers Squibb; Merck |
|
|
No Relationships to Disclose |